The Montreal-based company, founded in 2021, offers a research-grade diagnostic platform with 3D scanning and multiplexed detection capabilities. Their platform supports bio-interaction and bioimaging research, providing accurate and reliable cytopathology diagnostics for cancer. Vega BioImaging also offers plasmonic nanoparticles made from gold and silver alloys, which are used as optical markers for biochemical or biomedical diagnostics. Their innovative solutions aim to improve prognostics for immunotherapy and address the high error rate in the field of Clinical Immunohistochemistry (IHC).